Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16375382 | 0.85 | — | — | |
| SCHEMBL14752962 | 0.83 | ATM (0.41) | JAK1ATMALDH1A1MAPTGAA | |
| SCHEMBL24043005 | 0.81 | ATM (0.43) | ATMALDH1A1MAPTGAASMN1; SMN2 | |
| SCHEMBL1562179 | 0.79 | CA12 (0.37) | ALDH1A1MAPTSMN1; SMN2RAB9APDE10A | |
| SCHEMBL1562042 | 0.79 | HSD11B1 (0.42) | JAK1RAB9APDE10A | |
| SCHEMBL304311 | 0.79 | ATM (0.46) | ATMALDH1A1MAPTGAASMN1; SMN2 | |
| SCHEMBL12549405 | 0.78 | JAK1 (0.40) | JAK1CCR5ATMHRH3ALDH1A1 | |
| SCHEMBL12548977 | 0.78 | JAK1 (0.40) | JAK1CCR5ATMHRH3ALDH1A1 | |
| SCHEMBL12385847 | 0.78 | JAK1 (0.37) | JAK1CCR5ATMHRH3ALDH1A1 | |
| SCHEMBL1561877 | 0.77 | DPP4 (0.36) | ATMALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399461-B2 | Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-19 | — | — | US | claimed |
| US-20110136805-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION OF SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-09 | — | — | US | claimed |
| EP-2091925-B1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION OF SAME | BOEHRINGER INGELHEIM INT (DE) | 2011-04-06 | — | — | EP | claimed |
| EP-2091925-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION OF SAME | Boehringer Ingelheim International GmbH (DE) | 2009-08-26 | — | — | EP | claimed |
| EP-1966189-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-10 | — | — | EP | claimed |
| WO-2008055854-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION OF SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-15 | — | — | WO | claimed |
| EP-1921070-A1 | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-05-14 | — | — | EP | claimed |
| WO-2007068552-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | claimed |
| US-20070135463-A1 | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | HIMMELSBACH FRANK | 2007-06-14 | — | — | US | claimed |
| US-8399461-B2 | Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-19 | — | — | US | disclosed |
| EP-2373329-A2 | USE OF EPIDERMAL GROWTH FACTOR INHIBITORS IN THE TREATMENT OF VIRAL INFECTION | The Regents of the University of California (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20110236349-A1 | Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-09-29 | — | — | US | disclosed |
| US-20110136805-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION OF SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-09 | — | — | US | disclosed |
| EP-2091925-B1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION OF SAME | BOEHRINGER INGELHEIM INT (DE) | 2011-04-06 | — | — | EP | disclosed |
| EP-2091925-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION OF SAME | Boehringer Ingelheim International GmbH (DE) | 2009-08-26 | — | — | EP | disclosed |
| EP-1966189-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008055854-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION OF SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-15 | — | — | WO | disclosed |
| EP-1921070-A1 | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007068552-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135463-A1 | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | HIMMELSBACH FRANK | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136805-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION OF SAME | BPHL, CYP11B2, CYP11B1 | JAK1 85/4885CCR5 3405/4885ATM 566/4885 |
| US-20070135463-A1 | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | BPHL, CYP11B2, CYP11B1 | JAK1 183/4885CCR5 1827/4885ATM 540/4885 |
| US-20110236349-A1 | Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection | EGFR, HDGF, HGF | JAK1 899/4885CCR5 119/4885ATM 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.